



Resource impact statement

Resource impact

Published: 15 December 2021

www.nice.org.uk

No significant resource impact is anticipated

NICE has recommended [mogamulizumab](#) within its marketing authorisation, as an option for treating Sézary syndrome in adults who have had at least 1 systemic treatment. It is recommended only if the company provides mogamulizumab according to the commercial arrangement.

Mogamulizumab is also recommended as an option for treating mycosis fungoides in adults, only if:

- their condition is stage 2B or above and
- they have had at least 2 systemic treatments and
- the company provides mogamulizumab according to the commercial arrangement

These recommendations are not intended to affect treatment with mogamulizumab that was started in the NHS before the guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before the guidance was published, until they and their NHS clinician consider it appropriate to stop.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people). This is because the population size is small.

Patient experts at the committee meeting explained that the disease affects their health-related quality of life. Clinical experts described that people with these conditions have limited treatment options.

The company has a commercial arrangement (simple discount patient access scheme). This makes mogamulizumab available to the NHS with a discount. The size of the discount is commercial in confidence. For enquiries about the patient access scheme contact: PASUK@kyowakirin.com.

Mogamulizumab is commissioned by NHS England. Providers are NHS hospital trusts.